This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd

Prescribing information and adverse event reporting can be found via the link at the top right of the page

Would you treat me differently,
if you could see it on the outside?

Endometriosis is the second most common gynaecological condition in the UK.3 It affects one in ten women of reproductive age.2

Now Besins Healthcare introduces

Dimetrum® - dienogest 2mg

Dimetrum®: Indicated for the treatment of endometriosis1

Dimetrum (dienogest 2mg) is a fourth-generation synthetic progestin,4,5 derived from 19-nortestosterone, which is highly selective for progesterone receptors.6

Dienogest has:6

  • Direct antiproliferative activities
  • Immunologic activities4 and also causes atrophy of the endometriotic lesions.7
Dimetrum 2mg packaging

These are expected to contribute to the reduction of endometriosis-associated symptoms.6

Dimetrum® is generally well tolerated1,8,9

  • Most adverse events were mild to moderate intensity9
  • The most frequently reported undesirable effects under treatment with Dimetrum are headache (9.0%), breast discomfort (5.4%), depressed mood (5.1%) and acne (5.1%)1
  • Adverse event discontinuation rates were low.9

For special warnings, precautions, and contraindications please consult the SPC.

Dimetrum® provides symptom control for your patients

Dimetrum reduces endometriosis-associated pelvic pain (EAPP)10

In a randomised, double-blind, placebo-controlled, multicentre study of 198 women, Dimetrum was significantly more effective than placebo in reducing EAPP at 12 weeks (p<0.0001).10

Graph showing the change in EAPP during treatment with Dimetrum vs placebo[10]. The visual analogue scale (VAS) score for dienogest is lower than placebo at 4, 8 and 12 weeks of treatment (p<0.0001, n=198). Adapted from Strowitzki et al. 2010.[10]

In a literature review, Dimetrum was shown to reduce multiple types of endometriosis-associated pain:8

  • Pelvic pain
  • Dysmenorrhea
  • Dyspareunia
  • Dysuria
  • Dyschezia.

Dimetrum® provides disease control for your patients5,9,11

In a systematic review and meta-analysis, Dimetrum was shown to significantly reduce the rate of post-operative recurrence of endometriosis up to approximately three years, compared to post-operative patients not given Dimetrum (p<0.001).11

In an open-label, randomised, multicentre, 24-week comparative trial in 29 women with histologically confirmed endometriosis, Dimetrum was shown to significantly reduce the severity of endometriotic lesions compared to baseline (p<0.001).9

Dimetrum® compares well to established treatments6,8,12

Dimetrum has been shown to be as effective as gonadotropin-releasing hormone (GnRH) agonists.

In a study of 252 patients with confirmed endometriosis, dienogest 2 mg was as effective as Leuprolide acetate (LA) for treating EAPP at 24 weeks (p<0.0001).12

In a Japanese, randomised, double-blind, multicentre, controlled trial of 253 patients with endometriosis, dienogest 2 mg was as effective as intranasal buserelin acetate (BA) 900mcg in alleviating the symptoms of endometriosis at 24 weeks (p>0.05).6

Dimetrum® and cyst reduction

In a multicentre, prospective study of 81 patients with ovarian endometriosis, dienogest 2mg alone was significantly more effective in reducing the volume of endometriomas than a combined oral contraceptive (ethinyl estradiol 30 µg plus dienogest 2mg) (p<0.001).13

Graph showing a reduction in cyst volume for patients treated with dienogest 2mg alone vs a combined oral contraceptive. Adapted from Angioni et al. 2020.[13]

Time for change

Choose Dimetrum®
for endometriosis
support on the inside

Dimetrum for pain relief6,10

  • Effective therapy for reducing the painful symptoms of endometriosis at 12 weeks*10

  • Demonstrates an efficacy that is significantly superior to placebo*10

  • A Japanese study has shown an efficacy equivalent to therapy with GnRH agonists at 24 weeks†6

  • Provides progressive pain relief for up to 65 weeks.14

*In a randomised, double-blind, placebo-controlled, multicentre study of 198 women (p<0.0001).

†In a randomised, double-blind, multicentre, controlled trial of 271 patients with endometriosis (p>0.05).

Dimetrum for lesion reduction9

  • Shown to significantly reduce the severity of endometriotic lesions at 6 months (p<0.001)‡9

‡In an open-label, randomised, multicentre, 24-week comparative trial in 68 women (p<0.001).

Dimetrum for cyst reduction13

  • More effective in reducing ovarian cysts than a combined oral contraceptive.**13 

**In a multicentre, prospective study of 81 patients with ovarian endometriosis, dienogest 2 mg alone was significantly more effective in reducing the volumes of endometriomas than the combination of ethinyl estradiol 30 µg plus dienogest 2 mg (p<0.001).

Resources

Besins Healthcare (UK) Ltd does not recommend, endorse or accept liability for the following sites controlled by third-parties.

Please find below a selection of resources which you may find useful when treating patient suffering from endometriosis, or when expanding your knowledge of this condition:

References

  1. Dimetrum SPC
  2. World Health Organisation. Endometriosis. 2021. Available at: https://www.who.int/news-room/factsheets/detail/endometriosis. Accessed November 2022.
  3. University College London Hospitals. General information about Endometriosis. Available at https://www.uclh.nhs.uk/our-services/find-service/womens-health-1/gynaecology/endometriosis/general-information-aboutendometriosis Accessed November 2022.
  4. Caruso S. et al. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. Journal of Pain Research 2019; 12: 2371-2378.
  5. Andres Mde P, et al. ‘Dienogest in the treatment of endometriosis: systematic review.’ Arch Gynecol Obstet 2015;292(3):523-9.
  6. Harada T, et al. ‘Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, double-blind, multicenter, controlled trial.’ Fertil Steril 2009;91(3):675-81.
  7. Klipping C, et al. Ovulation-Inhibiting Effects of Dienogest in a Randomized, Dose-Controlled Pharmacodynamic Trial of Healthy Women. J Clin Pharmacol 2012; 52: 1704-1713.
  8. Murji A, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020 May;36(5):895-907. doi: 10.1080/03007995.2020.1744120. Epub 2020 Mar 31. PMID:32175777.
  9. Köhler G et al. Int J Gynaecol Obstet 2010;108: 21-25.
  10. Strowitzki T, et al. ‘Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study.’ Eur J Obstet Gynecol Reprod Biol 2010;151(2):193-8.
  11. Zakhari A, et al. Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2020 Nov-Dec;27(7):1503-1510. doi: 10.1016/j.jmig.2020.05.007. Epub 2020 May 16. PMID: 32428571.
  12. Strowitzki T, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010 Mar;25(3):633-41. doi:10.1093/humrep/dep469. Epub 2010 Jan 19. PMID: 20089522.
  13. Angioni S, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020 Jan;36(1):84-86. doi:10.1080/09513590.2019.1640674. Epub 2019 Jul 16. PMID: 31311360.
  14. Petraglia F, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2012;285:167–173.